|
|
3. Pfizer
Warren Buffett is well known as a buy-and-hold investor. But he recently led Berkshire Hathaway to sell its stake in Pfizer (NYSE:PFE). Just because Buffett sold Pfizer after holding it for a short period doesn't mean it's a smart move for other investors, though.
Actually, the long-term prospects for Pfizer look better than they have in years. The big pharmaceutical company's growth has been held back in the past by older drugs that no longer enjoy patent exclusivity. Pfizer isn't weighed down by those drugs anymore, though, thanks to the merger of its Upjohn unit with Mylan last November.
The company now expects to generate annual adjusted earnings-per-share growth of around 10% -- at least over the next five years. With Pfizer's juicy dividend thrown into the mix, investors should see solid total returns.
It's important to note, however, that Pfizer's earnings-growth projection doesn't include the impact of its COVID-19 vaccine BNT162b2. Pfizer expects the vaccine to rake in well over $18 billion this year. Although the company will split profits equally with its partner BioNTech, Pfizer's fortunes will definitely receive a huge boost from BNT162b2 in 2021 and beyond. Investors who buy and hold this popular Robinhood stock will likely be glad they did down the road. |
|
狗仔卡
发表于 2021-3-11 05:00 PM
提升卡
置顶卡
沉默卡
喧嚣卡
变色卡